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ABSTRACT  
Background: Perceived helpfulness of treatment is an important healthcare quality indicator. 
We examine probability and predictors of the two key components of this indicator for post-
traumatic stress disorder (PTSD). 
Methods: Data come from World Mental Health surveys in 21 countries.  Respondents who ever 
sought PTSD treatment (n=882) were asked if treatment was ever helpful and, if so, the number 
of professionals they had to see to obtain helpful treatment. Patients whose treatment was never 
helpful were asked how many professionals they saw. Parallel survival models were estimated 
for obtaining helpful treatment and persisting in help-seeking after earlier unhelpful treatments.  
Results: 52.8% of patients eventually received helpful treatment, but survival analysis suggests 
that 95.5% would have received helpful treatment if all patients persisted with up to five 
professionals after earlier unhelpful treatment. Only an estimated 23.1% of patients would persist 
to that extent. Odds of treatment being helpful were positively associated with pharmacotherapy 
provided by a mental health professional, short delays in help-seeking, absence of prior 
comorbid anxiety disorders, and absence of childhood adversities. These predictors differed in 
relative importance in predicting helpfulness of particular treatment encounters and persistence 
after earlier unhelpful treatment encounters.  
Conclusions and Relevance: Most PTSD treatment seekers will eventually receive treatment 
they consider helpful if they persist in seeking help after initially unhelpful encounters, but this 
might require seeing up to five professionals. The vast majority of patients who initially receive 
unhelpful treatment give up well before this point. 
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INTRODUCTION 
The World Mental Health (WMH) survey initiative has significantly advanced our understanding 
of the global epidemiology of trauma and posttraumatic stress disorder (PTSD) (Bromet, Karam, 
Koenen, & Stein, 2018).  WMH data were collected from more than 20 countries using 
coordinated, rigorous, and innovative interviewing methods to comprise the largest cross-
national dataset on trauma and PTSD to date.  The surveys have delineated rates of and risk 
factors for exposure to traumatic events (Benjet et al., 2016) and subsequent PTSD (Kessler et 
al., 2017), have clarified secondary psychiatric and medical morbidities (Kessler et al., 2011; 
Scott et al., 2016) as well as burden of disease (Kessler, Aguilar-Gaxiola, Alonso, Lee, & 
Koenen, 2018), and have provided data on health services use for PTSD in different contexts 
(Thornicroft et al., 2018).  WMH data have also been used to address several clinical questions, 
such as optimal diagnostic criteria and identification of those at risk for PTSD (Karam et al., 
2010; Stein et al., 2013; Stein et al., 2014). 
Nevertheless, several epidemiological and clinical aspects of the treatment of PTSD 
deserve further attention.  First, relatively little has been written about the perceived helpfulness 
of PTSD treatment (e.g., Cooper et al., 2017; Starzynski & Ullman, 2014).  With increased focus 
on the lived experience of individuals suffering from mental disorders and on patient-centered 
care (Bellamy et al., 2016), this is a key gap.  Second, there are few data on the longitudinal 
course of PTSD treatment, including data on perceived helpfulness over time, or data on 
persistence with treatment.  Such data may be useful in informing clinical treatment guidelines, 
which are currently mainly based on randomized trials in highly controlled settings (explanatory 
designs) rather than on sequential investigations in everyday contexts (pragmatic designs) 
(Fagiolini et al., 2017; Janiaud, Dal-Re, & Ioannidis, 2018). 
The probability of an individual with PTSD ever receiving helpful treatment is a joint 
function of the probability that any one treatment professional will be helpful and the probability 
that a patient will continue to seek treatment after an earlier treatment failure.  Questions in the 
WMH surveys about perceived helpfulness of initial and subsequent treatments of PTSD, as well 
as on a range of variables previously found to predict treatment outcomes (e.g., trauma type, 
socio-demographics, prior mental disorder, childhood adversities) provide a unique opportunity 
to examine predictors of both these components.  We aimed to address gaps in the literature on 
PTSD treatment by cross-national investigation of 1) the perceived helpfulness of initial and 
subsequent efforts to obtain treatment for PTSD and probability of persistence in help-seeking 
after initially obtaining unhelpful treatment as the two main components in a patient eventually 
finding a treatment that they consider helpful.  
METHODS 
Samples  
The World Health Organisation’s (WHO) World Mental Health (WMH) surveys are a 
coordinated set of community surveys administered to probability samples of the non-
institutionalized population in countries throughout the world 
(https://www.hcp.med.harvard.edu/wmh/; Kessler & Ustun, 2004). Data for the current report 
came from WMH surveys carried out in 16 countries - eight in countries classified by the World 
Bank as high-income (Argentina, Australia, Israel, Italy, Netherlands, Northern Ireland, Portugal, 
Saudi Arabia, Spain and United States) and six in countries classified as low- or middle- income 
(Brazil, Bulgaria, Colombia, Lebanon, Mexico and Romania). There were two surveys in 
Bulgaria, administered to separate samples in 2002-2006, and 2016-2017. Seventeen surveys 
were based on nationally representative household samples, whereas three were representative of 
selected Metropolitan Areas (Sao Paolo Brazil; Medellin Colombia; Japan), one was 
representative of selected regions (Murcia Spain), and three were representative of all urbanized 
areas (Colombia, Mexico; Argentina). Response rates ranged from 45.9% (France) to 97.2% 
(Medellin) and averaged 68.1% across surveys (see eTable 1). 
The interview schedule was developed in English and translated into other languages 
using a standardized WHO translation, back-translation and harmonization protocol (Harkness et 
al., 2008). Interviews were administered face-to-face in respondents’ homes after obtaining 
informed consent using procedures approved by local Institutional Review Boards. Interviews 
were in two parts. Part I was administered to all respondents and assessed core DSM-IV mental 
disorders (n=109,869 respondents across all surveys). Part II assessed additional disorders and 
correlates and was administered to 100% of respondents who met lifetime criteria for any Part I 
disorder and a probability subsample of other Part I respondents (n=61,775). Part II respondents 
were weighted to adjust for differential probabilities of selection into Part II and deviations 
between the sample and population demographic-geographic distributions. This weight resulted 
in prevalence estimates of Part I disorders in the weighted Part II sample being identical to those 
in the Part I sample (Heeringa et al., 2008).  
Measures 
Post-traumatic stress disorder: Diagnoses were based on Version 3.0 of the WHO’s 
Composite International Diagnostic Interview (CIDI; Kessler & Ustun, 2004) a fully-structured 
lay-administered diagnostic interview. DSM-IV criteria were used to define post-traumatic stress 
disorder (PTSD) along with a number of other anxiety disorders (generalized anxiety disorder, 
panic disorder, agoraphobia with or without panic disorder, specific phobia and social phobia,), 
mood disorders (major depressive disorder and bipolar disorder), and substance disorders 
(alcohol and drug abuse and dependence). The assessment of PTSD began with a series of 
questions about lifetime exposure to a wide range of traumatic experiences. When more than one 
lifetime traumatic experiences was reported, PTSD was assessed twice: once for symptoms 
associated with the traumatic experience the respondent reported as having caused the most 
distress and impairment; and a second time for one randomly selected other traumatic 
experience. PTSD was assessed only once among respondents who reported having only one 
traumatic experience in their life and not at all among respondents who never had a traumatic 
experience. Clinical reappraisal interviews were carried out in a number of WMH surveys using 
the lifetime non-patient version of the Structured Clinical Interview for DSM-IV (SCID; First, 
Spitzer, Gibbon, & Williams, 2002) as the gold standard. Good agreement was found between 
diagnoses of PTSD based on the CIDI and on blinded SCID clinician-administered reappraisal 
interviews (AUC=.69, positive predictive value [PPV]=.86; Haro et al., 2006). 
Helpful treatment: Respondents who met lifetime DSM-IV/CIDI criteria for PTSD were 
asked retrospectively about age-of-onset and were then asked whether they ever “talk(ed) to a 
medical doctor or other professional about” their PTSD and, if so, how old they were the first 
time they talked to a professional about their PTSD. “Other professionals” were defined broadly 
to include “psychologists, counselors, spiritual advisors, herbalists, acupuncturists, and other 
healing professionals.” Respondents answering yes were then asked whether they ever got 
treatment for their PTSD “that you considered helpful or effective (emphasis in original).” If so, 
they were asked how many professionals they ever talked to about their PTSD “up to and 
including the first time you ever got helpful treatment.” Respondents who said they never got 
helpful treatment, in comparison, were asked how many professionals they ever talked to about 
their PTSD.  
Predictors of helpful treatment: Socio-economic characteristics included age at first 
PTSD treatment (continuous), sex, marital status (married, never married, previously married), 
and education (in quartiles defined by within-country distributions). Lifetime comorbid 
conditions included number of anxiety, mood, and substance use disorders with first onsets prior 
to the age the respondent first sought treatment. Treatment type was defined as the cross-
classification of variables for: (i) whether the respondent reported receiving medication, talk 
therapy, or both, as of the age of first PTSD treatment; and; (ii) types of treatment providers seen 
as of that age, including mental health specialists (psychiatrist, psychiatric nurse, psychologist, 
psychiatric social worker, mental health counselor) with or without pharmacotherapy, primary 
care providers, human services providers (social worker or counselor in a social services agency, 
spiritual advisor), and complementary/alternative medicine (other type of healer or self-help 
group). Treatment timing included a dichotomous measure for whether the respondent’s first 
attempt to seek treatment occurred before 2000 or subsequently and a continuous variable for 
length of delay in years between age-of-onset of PTSD and age of initially seeking treatment.  
Analysis methods 
The sample for analysis was limited to people with onset of lifetime DSM-IV PTSD 
treatment on or after 1990 in order to minimise potential effects of recall bias. The probability of 
obtaining helpful treatment is a joint function of the probability that any one treatment provider 
will be helpful and the probability that a patient will continue to seek treatment after an initial 
treatment failure. In order to investigate these two components separately, we used discrete- 
event survival analysis to calculate the conditional and cumulative probabilities of: (i) obtaining 
helpful treatment after seeing between one and five professionals; and (ii) persisting in seeking 
treatment from up to five professionals after failing to obtain helpful treatment from the previous 
professional(s) seen (Halli & Rao, 1992). We then carried out parallel discrete-event survival 
analyses of the predictors of these two component outcomes using standard discrete-time 
methods and a logistic link function (Willett & Singer, 1993). Because the WMH sample designs 
used weighting and clustering, all statistical analyses were carried out using the Taylor series 
linearization method (Wolter, 1985), a design-based method implemented in the SAS 9.4 
program (SAS Institute Inc., 2016). Logistic regression coefficients and +/- 2 of their design-
based standard errors were exponentiated to create odds-ratios (ORs) and 95% confidence 
intervals (CIs). Significance tests of sets of coefficients were made using Wald χ2 tests based on 
design-corrected coefficient variance-covariance matrices. Statistical significance was evaluated 
consistently using two-sided design-based .05 level tests. 
RESULTS  
PTSD prevalence and treatment 
Lifetime prevalence of PTSD was 4.9% in high income countries, 2.3% in low/middle 
income countries, and 4.2% in the total sample. (Table 1) Among respondents with lifetime 
PTSD, 25.5% in high income countries ever sought treatment compared to 6.8% in low/middle 
income countries and 23.0% in the total sample. Roughly half these patients (52.8%) reported 
that treatment was helpful. This proportion did not differ significantly between high and 
low/middle income countries (53.1% vs. 43.8%, χ21=0.9, p=0.33).   
(Table 1 about here)  
Helpful PTSD treatment across professionals seen 
Probability of obtaining helpful PTSD treatment from the first professional seen was 
22.2% in the total sample. (Table 2) Conditional probabilities of subsequent professionals being 
helpful if they were seen after earlier unhelpful treatments were in the range 22.7-32.7% and did 
not vary significantly depending on number of prior unhelpful treatments (χ23=1.3, p=0.73). 
These proportions were very similar in high income vs. low/middle income countries.  
(Table 2 about here)  
Survival analysis based on these conditional probabilities suggests that the cumulative 
probability of receiving helpful treatment from at least one treatment provider would increase 
from 22.2% after the first professional seen to 47.6% if all patients continued to a second 
provider after a first treatment failure. This estimated cumulative probability would increase to 
an estimated 95.5% if all patients persevered in trying up to five professionals after earlier ones 
were unhelpful. These patterns were generally similar across country income levels. 
Persistence with PTSD treatment seeking following earlier unhelpful treatment  
In the total sample, 61.4% of patients who were not helped by the first professional seen 
persisted in seeing a second professional. Further persistence after unhelpful treatments from 
between 1 and 3 subsequent professionals was in the range 65.6-81.1% and varied significantly 
depending on number of prior unhelpful treatments (χ22=8.3, p=0.02). These proportions were 
very similar in high income vs. low/middle income countries.  
(Table 3 about here)  
However, not all patients persisted after each unhelpful attempt. Survival analysis based 
on the conditional probabilities suggests that the cumulative probability of persisting with up to 
five professionals in the face of prior treatments being unhelpful would be 23.1% in the total 
sample. Again patterns were generally similar across country income levels. 
Predictors of helpful PTSD treatment 
We noted above that 52.8% of the patients who sought treatment for their PTSD reported 
that they received helpful treatment. Logistic regression analysis at the person-level (i.e., 
ignoring the number of treatment providers consulted) pooled across this entire sample adjusting 
for between-country differences found that odds of obtaining helpful treatment was not 
significantly related to any of the socio-demographic variables considered (age of first PTSD 
treatment, sex, marital status at the time of initiating treatment, education level at the time of 
initiating treatment) or to the type of traumatic experience that caused the PTSD. (Table 4) 
However, five other predictors were significant. Length of delay in seeking treatment after onset 
of PTSD was inversely related to odds of treatment being helpful. Patients who first obtained 
treatment in 2000 or later were significantly less likely than those whose treatment began in 
earlier years to report obtaining helpful treatment. Treatment type was important: the highest 
odds of helpful treatment was associated with specialty mental health treatment and psychotropic 
medications and the lowest with treatment in the human services sector. Comorbid anxiety 
disorders were important, although this association was due to patients with exactly 2 but not 3+ 
other prior anxiety disorder being associated with low odds of PTSD treatment being helpful. 
And patients with a history of childhood adversity were less likely to obtain helpful treatment.  
(Table 4 about here)  
Decomposition showed that the pathways accounting for these significant associations 
varied considerably. In the case of delays in seeking treatment, the predictor was associated with 
both significantly decreased odds of a particular treatment provider being helpful and 
significantly decreased odds of persisting in seeking help from an additional provider after 
earlier unhelpful treatments. Historical time (i.e., 2000+ vs. 1999 or earlier), type of treatment 
received, and prior comorbid anxiety disorders, in comparison, were all non-significant 
predictors of a particular treatment provider being helpful, but significant predictors of 
persistence of seeking help after earlier unhelpful treatments. Childhood adversities, finally, were 
associated with both significantly decreased odds of a particular treatment provider being helpful 
and significantly decreased odds of persisting in seeking help.  
We carried out additional analyses to determine whether these significant predictors 
varied in importance between high and low/middle income countries, but none was statistically 
significant, although it needs to be noted that the number of patients in low/middle income 
countries was too small for powerful analyses of these interactions. We also investigated the 
possibility of time trends in the significant associations but only one emerged as significant at the 
.05 level: a strong association between childhood adversities and decreased odds of treatment 
being helpful.  
Discussion 
Several limitations of this study deserve emphasis; in particular assessment of key 
features of PTSD treatment and treatment response is based on sparse information.  Respondent 
judgments of the helpfulness of PTSD treatment were uncorroborated, uncontrolled, and 
retrospective.  More in-depth and formal measures of patient perceptions of care are available 
(Oades, Law, & Marshall, 2011; Uttaro, 2003), and only controlled trials using validated 
outcome measures can determine efficacy and effectiveness of such care.  Telescoping (dating 
past events as occurring more recently than they did) might have led to inaccuracy in estimates 
of the timing of treatment (Barsky, 2002), although we restricted the sample to those with onset 
of PTSD treatment no earlier than 1990 to help address limitations of recall.  In addition, 
assessment of the precise nature of PTSD treatment and its quality was limited to a small number 
of superficial questions, such as whether and when respondents “talk(ed) to a professional about 
their PTSD.” Furthermore, assessment of PTSD symptoms at the time of treatment was not 
undertaken. While findings here are therefore quite different in scope from those obtained from 
randomized controlled trials (RCTs) of PTSD interventions, they are important precisely because 
they address questions which that literature cannot.   
This is the first cross-national epidemiological study on perceived helpfulness of PTSD 
treatment.  Encouragingly, across the world, the slight majority (52.8%) of respondents with 
lifetime PTSD report treatment as helpful. And, importantly, we estimated that the vast majority 
(95.5%) would have experienced treatment as helpful if they had persevered in trying up to five 
professionals.  However, most patients are not helped by the first treatment received and many of 
these patients fail to persist in their help-seeking efforts, resulting in the proportions of patients 
helped being only slightly more than half of what it could be. The first of these results is 
consistent with RCTs of PTSD treatment, which demonstrate that even though a number of 
PTSD interventions are efficacious non-response rates are comparatively high and treatment 
effect sizes are comparatively low (Charney, Hellberg, Bui, & Simon, 2018; Difede, Olden, & 
Cukor, 2014). However, we are unaware of previous research that has investigated the issue of 
persistence in help-seeking. It is encouraging that across all countries, 61.4% of patients who 
were not helped by the first professional seen persisted in seeing another professional.  Still, not 
all people persisted after each unhelpful attempt and we estimated that the cumulative probability 
of persisting with up to five professionals needed was only 23.1%.  Although our projections 
require the assumption that people who do not persist with treatment would have had comparable 
outcomes to those who do, on the basis of these findings we would argue that clinical treatment 
guidelines for PTSD should strongly encourage clinicians and patients to persist with treatment.  
Similarly, conceptual frameworks to enhance person-centered PTSD care should be expanded to 
include factors addressing treatment motivations and expectations (Etingen et al., 2019; Sharma, 
Bamford, & Dodman, 2015).  
The data reported here on the predictors of helpfulness with PTSD treatment are also of 
interest in delineating the pathways that account for the helpfulness of individual clinical 
encounters and persistence in seeking help after initial unhelpful encounters. Delayed treatment 
seeking and childhood adversity were significant predictors of a particular PTSD treatment not 
being helpful as well as of lower persistence with help-seeking after unhelpful treatment.  In 
contrast, historical time (2000+ vs 1999 or earlier), type of treatment received (mental health and 
psychotropics vs treatment in the human services sector), and prior comorbid anxiety disorders 
predicted obtaining helpful treatment despite not being associated with a particular treatment 
provider being helpful because they predicted persistence in help-seeking after earlier unhelpful 
treatments.  
These findings are partially consistent with clinical studies of treatment response in 
PTSD, some of which have found a relationship between childhood adversity and worse outcome 
(Marshall et al., 1998), but they provide novel findings, such as those regarding delayed 
initiation of help-seeking, and generate hypotheses about mechanisms that deserve further 
investigation as potential intervention targets.  Thus, for example, it is possible that persisting 
with treatment is associated with more severe symptoms (those which require medication), and 
that persistence across treatment professionals equates to persisting until an adequate “dose” has 
been received.  The finding that those who received treatment as of 2000 were less likely to 
persist with treatment suggests that additional efforts may need to be devoted to psychoeducation 
efforts that emphasize that the best PTSD treatment still requires a trial-and-error approach and 
great persistence.  Increased treatment rates, without increased persistence rates, will not 
decrease prevalence optimally.  
The findings here are relevant to a number of currently topical discussions in global 
health, including those on the scale-up of efficacious treatment (Patel et al., 2018) and those on 
precision medicine (Seymour et al., 2017).  Given the treatment gap for common mental 
disorders such as PTSD, global mental health implementation science has investigated how best 
to scale-up efficacious interventions such as those outlined in mhGAP;  it is crucial that 
interventions are acceptable and accessible, and that quality controls ensure fidelity (Stein, Bass, 
Hofmann, 2019). Advances in data science have suggested that techniques such as machine 
learning may be useful in advancing precision psychiatry for a range of disorders, including 
PTSD;  this may allow clinicians to reduce the extent to which treatment approaches rely on 
trial-and-error, and to develop more individually targeted treatment strategies (Kessler, Bossarte, 
Luedtke, Zaslavsky, & Zubizarreta, 2019).  Measurement-based care and shared decision-making 
may also enhance patient-centered care of common mental disorders, including PTSD (Fortney 
et al., 2017). 
In summary, these data on PTSD treatment from the WMHS are encouraging in 
emphasizing how often treatment of PTSD is perceived as helpful in the community, but they 
also emphasize the need for more effective PTSD interventions.  From a public health 
perspective the findings here are consistent with calls for both scale-up of efficacious 
interventions for common mental disorders, as well as with calls for improved treatment 
targeting in mental health practice.  The estimation that across the world, with persistence in 
treatment, the vast majority of people with PTSD should eventually perceive treatment as 
helpful, is a novel one and may usefully inform current treatment guidelines.  Further work is 
needed to determine the extent to which targeted interventions to improve PTSD treatment 
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Table 1. Lifetime prevalence of DSM-IV post-traumatic stress disorder (PTSD), proportion of cases with lifetime PTS who obtained 
treatment, and proportion of treated cases who perceived treatment as helpful 
 
Category 
In the entire sample  
Among respondents with 
lifetime PTS  
Among cases that 
obtained lifetime PTS 
treatmenta 
% of PTS  % obtained treatmenta  
% perceived treatment 
as helpfulb 
n % (SE)  n % (SE)  n % (SE) 
I. Low/middle income countries            
Low/middle income countries 15557 2.3 (0.1)  605 6.8 (1.2)  53 43.8 (9.2) 
Colombia 2381 1.8 (0.4)  58 4.1 (3.1)  2 0.0 (0.0) 
Sao Paulo, Brazil 2942 3.2 (0.2)  160 8.3 (3.0)  17 27.5 (14.4) 
Bulgaria 2811 2.0 (0.3)  109 10.3 (2.8)  14 71.1 (15.7) 
Lebanon 1031 3.4 (0.6)  70 2.5 (1.8)  2 100.0 (0.0) 
Medellin, Colombia 1673 3.7 (0.6)  109 7.5 (2.6)  12 36.6 (16.0) 
Mexico 2362 1.5 (0.3)  68 3.1 (1.8)  4 32.0 (22.9) 
Romania 2357 1.2 (0.3)  31 6.9 (5.2)  2 65.8 (31.8) 
χ26 41.9*  6.9  1100.7* 
II. High-income countries            
High-income countries 46218 4.9 (0.1)  3349 25.5 (1.0)  829 53.1 (2.4) 
Argentina 2116 2.8 (0.3)  122 19.9 (3.7)  26 75.4 (10.9) 
Australia 8463 7.3 (0.4)  640 39.8 (2.6)  253 68.4 (3.7) 
Belgium 1043 2.7 (0.5)  51 8.1 (3.1)  8 0.0 (0.0) 
France 1436 3.9 (0.6)  98 25.2 (5.9)  29 0.0 (0.0) 
Germany 1323 1.7 (0.3)  54 19.3 (7.0)  12 0.0 (0.0) 
Israel 4859 1.6 (0.2)  73 12.0 (4.1)  8 47.3 (18.3) 
Italy 1779 2.4 (0.6)  65 6.3 (2.6)  5 0.0 (0.0) 
Japan 1682 1.3 (0.2)  38 16.7 (7.5)  4 67.4 (26.0) 
Murcia, Spain 1459 2.8 (0.5)  65 19.1 (3.7)  16 84.9 (11.5) 
Netherlands 1094 4.4 (0.8)  90 28.5 (7.8)  26 0.0 (0.0) 
New Zealand 7312 6.1 (0.3)  828 19.1 (2.0)  168 40.2 (5.7) 
Northern Ireland 1986 8.8 (0.7)  238 39.2 (4.3)  80 53.5 (7.1) 
Portugal 2060 5.3 (0.5)  180 28.7 (4.4)  64 45.2 (6.9) 
Spain 2121 2.2 (0.4)  85 16.6 (5.0)  23 0.0 (0.0) 
United States 5692 6.9 (0.4)  602 16.0 (1.5)  104 42.3 (4.2) 
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Table 1 continued. Lifetime prevalence of DSM-IV post-traumatic stress disorder (PTS), proportion of cases with lifetime PTS who 
obtained treatment, and proportion of treated cases who perceived treatment as helpful 
            
 In the entire sample  
Among respondents with 
lifetime PTS  
Among cases that 
obtained lifetime PTS 
treatmenta 
 % of PTS  
% obtained 
treatmenta  
% perceived treatment 
as helpfulb 
 n % (SE)  n % (SE)  n % (SE) 
Saudi Arabia 1793 3.6 (0.5)  120 2.4 (1.8)  3 100.0 (0.0) 
χ215 410.7*  130.3*  13181.4* 
III. Pooled countries            
All Countries 61775 4.2 (0.1)  3954 23.0 (0.9)  882 52.8 (2.3) 
χ222 597.0*  194.4*  14608.0* 
Low/middle income countries vs. High-income countries       
χ21 145.5*  61.4*  0.9 
      
Abbreviations: PTS, post-traumatic stress; SE, standard error.  
aCases are based on three conditions: (i) Respondents obtained PTS treatment; (ii) Year of first PTS treatment >= 1990; and (iii) Age at onset of PTS <= Year of first PTS treatment. 
bCases are based on four conditions: (i) Respondents obtained PTS treatment; (ii) Year of first PTS treatment >= 1990; (iii) Age at onset of PTS <= Year of first PTS treatment; and (iv) 




Table 2. Conditional and cumulative probabilities of PTS treatment being perceived as helpful after each professional seen, among respondents 





helpful after the 
1st professional 
seen 
 Treatment being 
perceived as 
helpful after the 
2nd professional 
seen 
 Treatment being 
perceived as 











helpful after the 5th 
professional seen 
         
n % (SE)  n % (SE)  n % (SE)  n % (SE)  n % (SE) 
I. Conditional probabilities                    
High-income countries 829 21.9 (2.2)  395 33.2 (2.9)  183 32.5 (3.9)  93 30.4 (8.1)  55 23.2 (6.0) 
Low/middle income countries 53 27.7 (2.4)  22 19.4 (6.0)  15 12.0 (1.1)  4 21.0 (16.6)  2 0.0 (0.0) 
All 882 22.2 (2.1)  417 32.7 (2.8)  198 31.4 (3.7)  97 30.1 (7.9)  57 22.7 (5.8) 
II. Cumulative probabilities          
High-income countries 829 21.9 (2.2)  829 47.8 (2.9)  829 64.8 (3.0)  829 75.5 (3.0)  829 95.5 (1.7) 
Low/middle income countries 53 27.7 (2.4)  53 41.7 (10.2)  53 48.7 (10.9)  53 59.5 (15.2)  53 100.0 (0.0) 
All 882 22.2 (2.1)  882 47.6 (2.8)  882 64.1 (2.9)  882 74.9 (3.0)  882 95.5 (1.7) 
                    
Abbreviations: PTS, post-traumatic stress; SE, standard error. 




Table 3. Conditional and cumulative probabilities of persistence with treatment after previous unhelpful attempts, among respondents 
with lifetime DSM-IV PTS who obtained treatment 
 
 
Saw the 2nd 
professional 
 Saw the 3rd 
professional 
 Saw the 4th 
professional 
 Saw the 5th 
professional 
Not helped by the 
1st professional they 
saw 
 Not helped by the 2nd 
professional they 
saw 
 Not helped by the 3rd 
professional they 
saw 
 Not helped by the 
4th professional they 
saw 
n % (SE)  n % (SE)  n % (SE)  n % (SE) 
I. Conditional probabilities                
High-income countries 683 61.5 (2.0)  263 70.0 (3.1)  132 68.2 (3.6)  70 81.8 (4.6) 
Low/middle income countries 36 58.0 (4.0)  18 84.1 (3.3)  13 27.3 (4.8)  3 57.9 (0.0) 
All 719 61.4 (1.9)  281 70.6 (3.0)  145 65.6 (3.5)  73 81.1 (4.4) 
II. Cumulative probabilities                
High-income countries 683 61.5 (2.0)  683 43.1 (2.7)  683 29.4 (2.5)  683 24.1 (2.6) 
Low/middle income countries 36 58.0 (4.0)  36 48.8 (11.0)  36 13.3 (6.9)  36 7.7 (5.4) 
All 719 61.4 (1.9)  719 43.4 (2.6)  719 28.4 (2.4)  719 23.1 (2.5) 
                
Abbreviations: PTS, post-traumatic stress; SE, standard error. 
 
                  . 
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Table 4. Predictors of helpful treatment and persistence (pooled across professionals seen), and predictors of perceived helpfulness of treatment (person level), 




Predicting helpful treatment 
pooled across professionals seen  
Model 2: 
Predicting persistence  
pooled across treatment failure  
Model 3:  
Predicting perceived 
helpfulness of treatment  
across people with PTS 
Prevalence Multivariate  Prevalence Multivariate  Prevalence Multivariate 
Mean/% (SE) AOR 95% CI  Mean/% (SE) AOR 95% CI  Mean/% (SE) AOR  95% CI 
Age at first post-traumatic stress treatment 34.8 (0.6) 1.01  (1.00-1.03)  35.1 (0.7) 1.00  (0.98-1.01)  35.7 (0.5) 1.00  (0.98-1.02) 
χ21   3.03    0.28    0.01 
Female 67.5 (2.6) 1.04  (0.72-1.51)  66.4 (2.6) 0.91  (0.60-1.38)  70.1 (2.3) 1.31  (0.77-2.22) 
χ21   0.05    0.18    0.99 
Marital status               
Never married 39.8 (2.2) 1.43  (0.97-2.13)  38.6 (2.3) 0.76  (0.48-1.22)  40.3 (1.9) 0.91 (0.54-1.54) 
Previously married 29.8 (2.6) 1.21  (0.79-1.83)  30.6 (2.7) 0.92  (0.58-1.47)  29.1 (2.0) 1.08  (0.63-1.85) 
χ22   3.54    1.30    0.29 
Education               
Low 8.8 (1.0) 0.59  (0.34-1.03)  9.8 (1.1) 0.69  (0.36-1.34)  10.2 (0.9) 0.44*  (0.23-0.87) 
Low-average 25.9 (2.4) 0.86  (0.55-1.35)  25.6 (2.5) 1.12  (0.70-1.80)  25.7 (2.0) 0.86  (0.49-1.49) 
High-average 33.3 (2.1) 0.76  (0.50-1.17)  34.1 (2.3) 0.92  (0.61-1.40)  31.5 (1.9) 0.60*  (0.38-0.95) 
Student 11.5 (1.4) 0.79  (0.44-1.44)  10.9 (1.6) 1.39  (0.65-2.95)  10.4 (1.2) 0.86  (0.38-1.98) 
χ24   4.46    3.46    9.22 
Treatment delay (years)a 9.5 (0.7) 0.98*  (0.97-1.00)  10.0 (0.8) 0.99*  (0.97-1.00)  9.4 (0.5) 0.98*  (0.96-1.00) 
χ21   6.76*    4.26*    4.95* 
Started PTS treatment ≥ 2000 (vs. 1990-1999) 58.9 (2.1) 0.79  (0.58-1.07)  60.1 (2.2) 0.50*  (0.33-0.76)  61.9 (1.9) 0.48*  (0.31-0.73) 
χ21   2.30    10.61*    11.73* 
Treatment typeb               
Mental health specialist + Psychotherapy 43.6 (1.9) 1.19  (0.77-1.84)  45.2 (1.9) 1.35  (0.77-2.37)  44.3 (1.9) 1.26  (0.72-2.18) 
Mental health specialist + Medication 65.8 (2.3) 1.36  (0.76-2.44)  65.2 (2.4) 1.81*  (1.23-2.65)  59.9 (2.2) 2.24*  (1.25-4.00) 
Human services 22.8 (2.4) 0.80  (0.53-1.23)  23.4 (2.6) 0.68  (0.45-1.04)  21.7 (1.9) 0.60*  (0.37-0.95) 
General medical 80.6 (1.6) 0.67*  (0.48-0.95)  81.7 (1.6) 1.54  (0.95-2.47)  77.4 (1.6) 0.88  (0.53-1.48) 
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Table 4 continued. Predictors of helpful treatment and persistence (pooled across professionals seen), and predictors of perceived helpfulness of treatment 
(person level), among people with lifetime DSM-IV PTS disorder 
 
 Model 1: Predicting helpful treatment 
pooled across professionals seen  
Model 2: 
Predicting persistence  
pooled across treatment failure  
Model 3:  
Predicting perceived 
helpfulness of treatment  
across people with PTS 
 Prevalence Multivariate  Prevalence Multivariate  Prevalence Multivariate 
 Mean/% (SE) AOR 95% CI  Mean/% (SE) AOR 95% CI  Mean/% (SE) AOR   95% CI 
Complementary/alternative medicine 25.6 (1.9) 1.00  (0.67-1.48)  26.3 (2.0) 0.87  (0.57-1.31)  23.6 (1.8) 0.98  (0.58-1.66) 
χ25   9.82    19.93*    13.07* 
Exactly 2 or more of the above 74.1 (2.1) 0.66 (0.32-1.35)  74.7 (2.2) 1.19  (0.67-2.13)  68.9 (2.1) 0.88  (0.42-1.85) 
χ21   1.30    0.36    0.11 
χ26   10.21    31.92*    20.60* 
Number of lifetime anxiety disordersc               
3 or more lifetime anxiety disordersc 31.0 (2.3) 0.85  (0.60-1.19)  31.2 (2.3) 1.38 (0.91-2.11)  27.1 (1.8) 1.28  (0.81-2.00) 
Exactly 2 lifetime anxiety disordersc 29.4 (2.1) 0.63*  (0.43-0.93)  30.9 (2.3) 0.72 (0.48-1.09)  30.5 (2.0) 0.52*  (0.33-0.82) 
χ22   6.23*    11.04*    17.65* 
Mood disorder               
Major depressive disorder 48.8 (2.4) 1.01 (0.73-1.38)  49.3 (2.6) 1.21 (0.82-1.79)  48.1 (1.8) 1.15 (0.75-1.74) 
Bipolar disorder 11.9 (1.5) 1.16 (0.64-2.11)  12.3 (1.7) 1.02 (0.61-1.69)  11.2 (1.3) 0.88 (0.47-1.64) 
χ22   0.26    1.12    0.91 
Substance use disorder               
Alcohol and/or drug abuse 34.6 (2.5) 0.96  (0.69-1.34)  35.2 (2.5) 1.30 (0.90-1.88)  30.1 (2.2) 1.16 (0.76-1.76) 
Alcohol or drug dependence but not abuse 2.4 (0.5) 1.75  (0.66-4.60)  2.3 (0.5) 1.36 (0.76-2.44)  2.5 (0.5) 1.54 (0.54-4.35) 
χ22   1.40    2.51    0.98 
χ26   8.32    15.65*    22.41* 
PTSD events            
Exposure to organized violenced 16.0 (1.8) 0.57* (0.36-0.89)  17.4 (1.9) 1.20 (0.75-1.90)  13.8 (1.3) 0.73 (0.39-1.37) 
Participation in organized violencee 42.5 (2.4) 1.15 (0.88-1.52)  42.8 (2.6) 1.07 (0.73-1.57)  40.3 (2.2) 1.13 (0.75-1.69) 
Physical violence victimizationf 31.9 (2.3) 0.52* (0.37-0.74)  32.8 (2.4) 1.68* (1.12-2.51)  25.8 (2.0) 0.79 (0.48-1.30) 
Sexual violence victimizationg 64.1 (2.0) 1.48* (1.08-2.01)  63.5 (2.1) 1.00 (0.70-1.43)  62.9 (1.9) 1.38 (0.93-2.05) 
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Table 4 continued. Predictors of helpful treatment and persistence (pooled across professionals seen), and predictors of perceived helpfulness of treatment 
(person level), among people with lifetime DSM-IV PTS disorder 
 
Model 1: 
Predicting helpful treatment 
pooled across professionals seen  
Model 2: 
Predicting persistence  
pooled across treatment failure  
Model 3:  
Predicting perceived 
helpfulness of treatment  
across people with PTS 
 Prevalence Multivariate  Prevalence Multivariate  Prevalence Multivariate 
 Mean/% (SE) AOR 95% CI  Mean/% (SE) AOR 95% CI  Mean/% (SE) AOR 95% CI 
Accidents/injuriesh 48.9 (2.4) 1.01 (0.68-1.50)  49.9 (2.6) 1.05 (0.73-1.50)  47.6 (1.9) 1.04 (0.68-1.59) 
Otherj 64.0 (2.4) 1.02 (0.75-1.38)  64.1 (2.6) 0.92 (0.63-1.34)  63.4 (2.0) 0.95 (0.61-1.47) 
χ26   26.09*    8.50    4.17 
Childhood adversities               
Family dysfunctionj 29.2 (1.4) 0.87 (0.66-1.15)  32.0 (1.5) 0.81 (0.58-1.13)  30.4 (1.4) 0.74 (0.49-1.10) 
Otherk 14.3 (1.1) 0.64* (0.46-0.90)  16.3 (1.2) 0.52* (0.38-0.72)  16.5 (1.1) 0.39* (0.26-0.58) 
χ22   8.15*    18.89*    24.29* 
Global χ230   98.10*    184.34*    100.12* 
               
Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; PTS, post-traumatic stress; SE, standard error, PTSD, post-traumatic stress disorder.  
*Significant at the .05 level, two sided test. 
aTreatment delay (years) = Age at first PTS treatment – Age at onset of PTS. 
bTreatment providers: mental health specialists (psychiatrist, psychiatric nurse, psychologist, psychiatric social worker, mental health counselor), primary care providers, human services providers (social worker or 
counselor in a social services agency, spiritual advisor), and complementary/alternative medicine (other type of healer or self-help group).  
cLT anxiety disorders include generalized anxiety disorder, panic disorder, agoraphobia with or without panic disorder, posttraumatic stress disorder, specific phobia and social phobia.  
dExposure to organized violence includes relief worker in war zone, civilian in war zone, civilian in region of terror, refugee and kidnapped.  
eParticipation in organized violence includes witnessed death/dead body/serious injury, accidentally caused serious injury/death, combat experience, purposely injured/tortured/killed someone and witnessed 
atrocities.  
fPhysical violence victimization includes beaten by caregiver, beaten by someone else and witnessed physical fight at home. 
gSexual violence victimization includes raped, sexually assaulted, stalked, beaten by spouse/romantic partner, trauma to loved one, some other trauma and private trauma. 
hAccidents/injuries includes natural disaster, toxic chemical exposure, automobile accident, life-threatening illness, child with serious illness and other life-threatening accident.   
iOther includes mugged/threatened with a weapon, human-made disaster and unexpected death of a loved one. 
jFamily dysfunction includes physical abuse, sexual abuse, neglect, parent mental disorder, parent substance disorder, parent criminal behavior and family violence.  
kOther includes parent died, parent divorced, other parent loss, physical illness and economic adversity.       
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eTable 1.  WMH sample characteristics by World Bank income categoriesa 
    Sample size  












range Part I Part II 
Part II and 




I. Low and middle income countries       
Brazil - São Paulo São Paulo 
Megacity 
São Paulo metropolitan area. 2005-8 18-93 5,037 2,942 -- 81.3 
Bulgaria NSHS 2002-6 Nationally representative. 2002-6 18-98 5,318 2,233 741 72.0 
Bulgaria 2 NNSHS 2016-17 Nationally representative. 2016-17 18-91 1,508 578 -- 61.0 
Colombia NSMH All urban areas of the country (approximately 73% of the 
total national population). 
2003 18-65 4,426 2,381 1,731 87.7 
Colombia - Medellín MMHHS Medellín metropolitan area. 2011-12 19-65 3,261 1,673 -- 97.2 
Lebanon LEBANON Nationally representative. 2002-3 18-94 2,857 1,031 595 70.0 
Mexico M-NCS All urban areas of the country (approximately 75% of the 
total national population).  
2001-2 18-65 5,782 2,362 1,736 76.6 
Romania RMHS Nationally representative. 2005-6 18-96 2,357 2,357 -- 70.9 
TOTAL     (30,546) (15,557) (4,803) 77.2 
II. High-income countries       
Argentina AMHES Eight largest urban areas of the country (approximately 
50% of the total national population). 
2015 18-98 3,927 2,116 -- 77.3 
Australiaf NSMHWB Nationally representative. 2007 18-85 8,463 8,463 -- 60 
Belgium ESEMeD Nationally representative. The sample was selected from 
a national register of Belgium residents. 
2001-2 18-95 2,419 1,043 486 50.6 
France ESEMeD Nationally representative. The sample was selected from 
a national list of households with listed telephone 
numbers.  
2001-2 18-97 2,894 1,436 727 45.9 
Germany ESEMeD Nationally representative.  2002-3 19-95 3,555 1,323 621 57.8 
Israel NHS Nationally representative. 2003-4 21-98 4,859 4,859 -- 72.6 
Italy ESEMeD Nationally representative. The sample was selected from 
municipality resident registries. 
2001-2 18-100 4,712 1,779 853 71.3 
Japan WMHJ 2002-6 Eleven metropolitan areas.  2002-6 20-98 4,129 1,682 -- 55.1 
Netherlands ESEMeD Nationally representative. The sample was selected from 
municipal postal registries. 
2002-3 18-95 2,372 1,094 516 56.4 
New Zealandf NZMHS Nationally representative. 2004-5 18-98 12,790 7,312 -- 73.3 
Northern Ireland NISHS Nationally representative. 2005-8 18-97 4,340 1,986 -- 68.4 
Portugal NMHS Nationally representative. 2008-9 18-81 3,849 2,060 1,070 57.3 
Saudi Arabiaf SNMHS Nationally representative 2013-16 18-65 3,638 1,793 -- 61.0 
Spain ESEMeD Nationally representative. 2001-2 18-98 5,473 2,121 960 78.6 
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eTable 1 continued.  WMH sample characteristics by World Bank income categoriesa 
    Sample size  












range Part I Part II 
Part II and 




Spain - Murcia PEGASUS- Murcia Murcia region. Regionally representative.  2010-12 18-96 2,621 1,459 -- 67.4 
United States NCS-R Nationally representative. 2001-3 18-99 9,282 5,692 3,197 70.9 
TOTAL     (79,323) (46,218) (8,430) 65.1 
III. TOTAL     (109,869) (61,775) (13,233) 68.1 
 
 
aThe World Bank (2012) Data. Accessed May 12, 2012 at: http://data.worldbank.org/country. Some of the WMH countries have moved into new income categories since the surveys were conducted. The income 
groupings above reflect the status of each country at the time of data collection. The current income category of each country is available at the preceding URL. 
bNSHS (Bulgaria National Survey of Health and Stress); NSMH (The Colombian National Study of Mental Health); MMHHS (Medellín Mental Health Household Study); LEBANON (Lebanese Evaluation of the 
Burden of Ailments and Needs of the Nation); M-NCS (The Mexico National Comorbidity Survey); RMHS (Romania Mental Health Survey); AMHES (Argentina Mental Health Epidemiologic Survey); NSMHWB 
(National Survey of Mental Health and Wellbeing); ESEMeD (The European Study Of The Epidemiology Of Mental Disorders); NHS (Israel National Health Survey); WMHJ2002-2006 (World Mental Health Japan 
Survey); NZMHS (New Zealand Mental Health Survey); NISHS (Northern Ireland Study of Health and Stress); NMHS (Portugal National Mental Health Survey); SNMHS (Saudi National Mental Health Survey); 
PEGASUS-Murcia (Psychiatric Enquiry to General Population in Southeast Spain-Murcia);NCS-R (The US National Comorbidity Survey Replication).    
cMost WMH surveys are based on stratified multistage clustered area probability household samples in which samples of areas equivalent to counties or municipalities in the US were selected in the first stage 
followed by one or more subsequent stages of geographic sampling (e.g., towns within counties, blocks within towns, households within blocks) to arrive at a sample of households, in each of which a listing of 
household members was created and one or two people were selected from this listing to be interviewed. No substitution was allowed when the originally sampled household resident could not be interviewed. 
These household samples were selected from Census area data in all countries other than France (where telephone directories were used to select households) and the Netherlands (where postal registries were 
used to select households). Several WMH surveys (Belgium, Germany, Italy, Spain-Murcia) used municipal, country resident or universal health-care registries to select respondents without listing households. The 
Japanese sample is the only totally un-clustered sample, with households randomly selected in each of the 11 metropolitan areas and one random respondent selected in each sample household. 17 of the 24 
surveys are based on nationally representative household samples.     
dArgentina, Australia, Brazil, Bulgaria 2 (2016-17), Colombia-Medellin, Israel, Japan, New Zealand, Northern Ireland, Romania, Saudi Arabia and Spain-Murcia did not have an age restricted Part 2 sample. All other 
countries were age restricted to ≤ 44. 
eThe response rate is calculated as the ratio of the number of households in which an interview was completed to the number of households originally sampled, excluding from the denominator households known 
not to be eligible either because of being vacant at the time of initial contact or because the residents were unable to speak the designated languages of the survey. The weighted average response rate is 68.1%. 

















eTable 2. Predictors of helpful treatment and persistence (pooled across professionals seen), and predictors of perceived helpfulness of treatment (person 
level), among people with lifetime DSM-IV PTS disorder (included only significant predictors from Table 4) 
 
 Model 1: Predicting helpful 
treatment pooled across 
professionals seen  
Model 2: Predicting persistence 
pooled across treatment failure  
Model 3: Predicting perceived 
helpfulness of treatment across 
people with PTS 
Prevalence Multivariate  Prevalence Multivariate  Prevalence Multivariate 
Mean/% (SE) AOR 95% CI  Mean/% (SE) AOR 95% CI  Mean/% (SE) AOR  95% CI 
Age at first post-traumatic stress treatment 34.8 (0.6) 1.01  (1.00-1.02)  35.1 (0.7) 0.99 (0.98-1.00)  35.7 (0.5) 1.00  (0.99-1.01) 
χ21   1.82    1.28    0.04 
Treatment delay (years)a 9.5 (0.7) 0.98*  (0.97-1.00)  10.0 (0.8) 0.99*  (0.97-1.00)  9.4 (0.5) 0.98*  (0.96-1.00) 
χ21   6.95*    4.05*    5.82* 
Started PTS treatment ≥ 2000 (vs. 1990-1999) 58.9 (2.1) 0.84  (0.62-1.13)  60.1 (2.2) 0.50*  (0.33-0.76)  61.9 (1.9) 0.48*  (0.31-0.75) 
χ21   1.30    10.49*    10.40* 
Treatment typeb               
Mental health specialist + Psychotherapy 43.6 (1.9)  1.01 (0.68-1.50)  45.2 (1.9) 1.48 (0.92-2.36)  44.3 (1.9) 1.19  (0.75-1.89) 
Mental health specialist + Medication 65.8 (2.3) 1.07 (0.73-1.57)  65.2 (2.4) 1.98*  (1.44-2.72)  59.9 (2.2) 2.03*  (1.32-3.13) 
Human services 22.8 (2.4)  0.79 (0.51-1.20)  23.4 (2.6) 0.72 (0.48-1.10)  21.7 (1.9) 0.60*  (0.36-0.98) 
General medical 80.6 (1.6) 0.61* (0.44-0.83)  81.7 (1.6) 1.75* (1.13-2.70)  77.4 (1.6) 0.88  (0.50-1.52) 
Complementary/alternative medicine 25.6 (1.9) 0.96 (0.65-1.41)  26.3 (2.0) 0.90 (0.61-1.33)  23.6 (1.8) 1.01  (0.61-1.66) 
χ25   9.90    38.33*    19.90* 
Number of lifetime anxiety disordersc               
3 or more lifetime anxiety disordersc 31.0 (2.3) 0.91 (0.65-1.27)  31.2 (2.3) 1.47 (0.97-2.24)  27.1 (1.8) 1.35  (0.86-2.11) 
Exactly 2 lifetime anxiety disordersc 29.4 (2.1)  0.63* (0.43-0.93)  30.9 (2.3) 0.73 (0.49-1.08)  30.5 (2.0) 0.53*  (0.33-0.85) 
χ22   8.00*    12.14*    19.19* 
PTSD events            
Exposure to organized violenced 16.0 (1.8) 0.56* (0.35-0.89)  17.4 (1.9) 1.21 (0.79-1.85)  13.8 (1.3) 0.77 (0.41-1.43) 
Participation in organized violencee 42.5 (2.4) 1.20 (0.90-1.60)  42.8 (2.6) 1.17 (0.80-1.73)  40.3 (2.2) 1.11 (0.75-1.65) 
Physical violence victimizationf 31.9 (2.3) 0.51* (0.36-0.73)  32.8 (2.4) 1.70* (1.20-2.42)  25.8 (2.0) 0.74 (0.45-1.20) 
Sexual violence victimizationg 64.1 (2.0) 1.49* (1.10-2.02)  63.5 (2.1) 0.98 (0.70-1.36)  62.9 (1.9) 1.46* (1.00-2.13) 




eTable 2 continued. Predictors of helpful treatment and persistence (pooled across professionals seen), and predictors of perceived helpfulness of treatment 
(person level), among people with lifetime DSM-IV PTS disorder (included only significant predictors from Table 4) 
 
Model 1: 
Predicting helpful treatment 
pooled across professionals seen  
Model 2: 
Predicting persistence  
pooled across treatment failure  
Model 3:  
Predicting perceived 
helpfulness of treatment  
across people with PTS 
 Prevalence Multivariate  Prevalence Multivariate  Prevalence Multivariate 
 Mean/% (SE) AOR 95% CI  Mean/% (SE) AOR 95% CI  Mean/% (SE) AOR   95% CI 
Otheri 64.0 (2.4) 1.02 (0.76-1.38)  64.1 (2.6) 0.92 (0.62-1.34)  63.4 (2.0) 0.95 (0.62-1.44) 
χ26   26.08*    13.27*    5.36 
Childhood adversities               
Family dysfunctionj 29.2 (1.4) 0.87 (0.66-1.13)  32.0 (1.5) 0.80 (0.59-1.10)  30.4 (1.4) 0.72 (0.49-1.07) 
Otherk 14.3 (1.1) 0.67* (0.48-0.94)  16.3 (1.2) 0.51* (0.38-0.70)  16.5 (1.1) 0.40* (0.27-0.58) 
χ22   6.65*    23.56*    25.52* 
Global χ218   70.40*    133.04*    81.75* 
               
Abbreviations. AOR, adjusted odds ratio; CI, confidence interval; PTS, post-traumatic stress; SE, standard error; PTSD, post-traumatic stress disorder. 
*Significant at .05 level, two sided test. 
aTreatment delay (years) = Age at first PTS treatment – Age at onset of PTS.  
bTreatment providers: mental health specialists (psychiatrist, psychiatric nurse, psychologist, psychiatric social worker, mental health counselor), primary care providers, human services providers (social worker or 
counselor in a social services agency, spiritual advisor), and complementary/alternative medicine (other type of healer or self-help group).   
cLT anxiety disorders include generalized anxiety disorder, panic disorder, agoraphobia with or without panic disorder, posttraumatic stress disorder, specific phobia and social phobia. 
dExposure to organized violence includes relief worker in war zone, civilian in war zone, civilian in region of terror, refugee and kidnapped.   
eParticipation in organized violence includes witnessed death/dead body/serious injury, accidentally caused serious injury/death, combat experience, purposely injured/tortured/killed someone and witnessed atrocities. 
fPhysical violence victimization includes beaten by caregiver, beaten by someone else and witnessed physical fight at home.   
gSexual violence victimization includes raped, sexually assaulted, stalked, beaten by spouse/romantic partner, trauma to loved one, some other trauma and private trauma.  
hAccidents/injuries includes natural disaster, toxic chemical exposure, automobile accident, life-threatening illness, child with serious illness and other life-threatening accident. 
iOther includes mugged/threatened with a weapon, human-made disaster and unexpected death of a loved one.   
jFamily dysfunction includes physical abuse, sexual abuse, neglect, parent mental disorder, parent substance disorder, parent criminal behavior and family violence.  




eTable 3. Interaction between main effects and historical time to predict helpful treatment and persistence (pooled across professionals seen), and predictors of 
perceived helpfulness of treatment (person level), among people with lifetime DSM-IV PTS disorder 
 
 Model 1: Predicting helpful 
treatment pooled across 
professionals seen  
Model 2: Predicting persistence 
pooled across treatment failure  
Model 3: Predicting perceived 
helpfulness of treatment across 
people with PTS 
Prevalence Multivariate  Prevalence Multivariate  Prevalence Multivariate 
Mean/% (SE) AOR 95% CI  Mean/% (SE) AOR 95% CI  Mean/% (SE) AOR  95% CI 
Interaction terms between each predictor and 
historical time               
Treatment delay (years)a 6.4 (0.7) 0.99  (0.97-1.02)  7.0 (0.8) 0.96*  (0.93-0.98)  6.8 (0.5) 0.97  (0.93-1.00) 
χ21   0.53    9.81*    3.59 
Treatment typeb               
Mental health specialist + Psychotherapy 22.7 (1.3)  1.33 (0.78-2.28)  24.1 (1.4) 0.32* (0.16-0.62)  26.6 (1.5) 0.65  (0.29-1.46) 
Mental health specialist + Medication 37.0 (2.3) 1.31 (0.64-2.68)  37.1 (2.5) 0.73  (0.31-1.72)  36.5 (1.9) 1.06  (0.44-2.55) 
Human services 14.0 (2.2)  1.04 (0.43-2.54)  14.9 (2.4) 0.71 (0.28-1.81)  14.2 (1.7) 0.90  (0.30-2.66) 
General medical 45.7 (2.3) 0.72 (0.36-1.46)  47.8 (2.4) 0.91 (0.39-2.10)  45.7 (2.0) 0.61  (0.24-1.58) 
Complementary/alternative medicine 13.8 (1.5) 0.84 (0.43-1.63)  14.9 (1.7) 0.37* (0.16-0.90)  14.4 (1.5) 0.40  (0.15-1.04) 
χ25   3.13    21.28*    6.52 
Number of lifetime anxiety disordersc               
3 or more lifetime anxiety disordersc 19.4 (2.2) 1.04 (0.51-2.11)  20.0 (2.3) 1.39 (0.64-3.02)  18.1 (1.8) 1.06  (0.50-2.26) 
Exactly 2 lifetime anxiety disordersc 18.0 (1.8)  0.77 (0.35-1.70)  19.2 (2.0) 1.51 (0.64-3.57)  19.2 (1.7) 1.16  (0.42-3.24) 
χ22   0.56    1.15    0.09 
Childhood adversities               
Family dysfunctiond 16.3 (1.1) 0.40* (0.25-0.65)  19.1 (1.2) 0.85 (0.38-1.89)  18.4 (1.1) 0.46* (0.21-0.99) 
Othere 8.8 (0.7) 0.51* (0.28-0.91)  10.7 (0.9) 1.06 (0.52-2.16)  10.9 (0.9) 0.56 (0.26-1.19) 
χ22   20.23*    0.18    6.12* 
Global χ210   33.46*    30.97*    23.41* 
               
Abbreviations. AOR, adjusted odds ratio; CI, confidence interval; PTS, post-traumatic stress; SE, standard error. 
*Significant at .05 level, two sided test.  
aTreatment delay (years) = Age at first PTS treatment – Age at onset of PTS. 
bTreatment providers: mental health specialists (psychiatrist, psychiatric nurse, psychologist, psychiatric social worker, mental health counselor), primary care providers, human services providers (social worker or 
counselor in a social services agency, spiritual advisor), and complementary/alternative medicine (other type of healer or self-help group). 
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eTable 3 continued. Interaction between main effects and historical time to predict treatment and persistence (pooled across professionals 
seen), and predictors of perceived helpfulness of treatment (person level), among people with lifetime DSM-IV PTS disorder 
cLT anxiety disorders include generalized anxiety disorder, panic disorder, agoraphobia with or without panic disorder, posttraumatic stress disorder, specific phobia and social phobia.  
dFamily dysfunction includes physical abuse, sexual abuse, neglect, parent mental disorder, parent substance disorder, parent criminal behavior and family violence.  
eOther includes parent died, parent divorced, other parent loss, physical illness and economic adversity.         
                   
          
 
